O. Osiyemi

发表

Doravirine dose Selection and 96-Week Safety and Efficacy versus Efavirenz in Antiretroviral Therapy-Naive Adults with HIV-1 Infection in a Phase IIb Trial

J. Gatell, H. Teppler, F. Raffi, 2019, Antiviral therapy.

Gram-positive pneumonia

G. Dickinson, O. Osiyemi, 2000, Current infectious disease reports.

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

W. Spreen, D. Margolis, A. Mills, 2021, AIDS (London, England).

Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients

J. Gatell, H. Teppler, Charlotte M. Harvey, 2014, Journal of the International AIDS Society.

Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial.

Samit R. Joshi, G. McComsey, Samir K. Gupta, 2016, The lancet. HIV.

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.

D. Ward, J. Gallant, M. Johnson, 2016, The lancet. HIV.

Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study

S. Treon, M. Ramgopal, S. Coutre, 2022, Open forum infectious diseases.

A Phase 2b randomised, controlled, partially blinded trial of the HIV Nucleoside Reverse Transcriptase Inhibitor BMS-986001 (AI467003): Weeks 24 and 48 Efficacy, Safety, Bone and Metabolic Results

Samit R. Joshi, G. McComsey, Samir K. Gupta, 2016 .

Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks.

J. Currier, M. Yin, J. Mrus, 2011, AIDS patient care and STDs.

Antibiotic Susceptibilities of Bacteria Isolated within the Oral Flora of Florida Blacktip Sharks: Guidance for Empiric Antibiotic Therapy

E. Ritter, O. Osiyemi, R. Borrego, 2014, PloS one.

1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis

D. Asmuth, J. Slim, J. Eron, 2020, Open Forum Infectious Diseases.

Cerebral phaeohyphomycosis due to a novel species: report of a case and review of the literature.

T. Cleary, O. Osiyemi, L. Dowdy, 2001, Transplantation.

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression: pOLAR month 12 results.

W. Spreen, D. Margolis, A. Mills, 2021, AIDS (London).

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

B. Gazzard, K. Tashima, M. Shields, 2019, The Lancet.

116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study

W. Spreen, D. Margolis, A. Mills, 2020 .

Pharmacokinetics of Total and Unbound Etravirine in HIV-1–Infected Pregnant Women

M. Ramgopal, C. Zorrilla, H. Crauwels, 2016, Journal of acquired immune deficiency syndromes.

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

J. Routy, S. De Wit, Kimberly Smith, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV

R. Dagan, J. Molina, L. Mohapi, 2021, AIDS.

Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy.

R. Bertz, C. Zorrilla, T. Eley, 2013, AIDS research and human retroviruses.

Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study

C. Zorrilla, H. Crauwels, V. Hillewaert, 2018, Infectious Diseases and Therapy.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Pharmacokinetics of once-daily Etravirine without and with Once-daily Darunavir/ritonavir in Antiretroviral-Naive HIV type-1-Infected Adults

P. Ruane, J. Lalezari, T. Kakuda, 2010, Antiviral therapy.

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study

M. Saag, M. Ramgopal, D. Brainard, 2021, Journal of acquired immune deficiency syndromes.

Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study

J. van Lunzen, J. Gatell, A. Antinori, 2016, Journal of acquired immune deficiency syndromes.

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority t

S. Oka, S. Walmsley, G. di Perri, 2023, The lancet. HIV.

Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies

P. Altmeyer, G. Rahav, D. Zeltser, 2018, Antimicrobial Agents and Chemotherapy.

Ceftaroline and gentamicin for the treatment of daptomycin‐non‐susceptible meticillin‐resistant Staphylococcus aureus bacteraemia and endocarditis in a pregnant patient

R. Richardson, Jennifer Kuretski, O. Osiyemi, 2014 .

Total and unbound darunavir (DRV) pharmacokinetics (PK) in HIV‐1‐infected pregnant women

P. Verboven, V. Hillewaert, S. Yasin, 2012 .

Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

M. Ramgopal, A. Mills, O. Osiyemi, 2024, The lancet. HIV.

Reduced exposure to darunavir and cobicistat in HIV‐1‐infected pregnant women receiving a darunavir/cobicistat‐based regimen

H. Crauwels, O. Osiyemi, K. Brown, 2019, HIV medicine.